Lumizyme® (alglucosidase alfa)

Lumizyme (alglucosidase alfa) is covered only for the FDA‑approved indication of Pompe disease and not for off‑label or expanded uses. Coverage requires confirmation by deficient acid α‑glucosidase activity (blood, fibroblasts, or muscle) or molecular genetic testing, prescription by or consultation with a geneticist, neurologist, metabolic disorder or lysosomal storage disorder specialist, documentation of clinical need, is authorized up to 12 months, and follows dosing of 20 mg/kg IV every 2 weeks.

"Treatment of individuals with Pompe disease (acid α-glucosidase deficiency) — FDA-approved indication."

Sign up to see full coverage criteria, indications, and limitations.